New three-year data for Roche’s Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA)

PRESS RELEASE Research Findings


F. Hoffmann-La Roche Ltd.

Basel, 29 April 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new three-year data from the FIREFISH study, including one-year data from the open label extension, reinforcing the long-term efficacy and safety of Evrysdi® (risdiplam) in infants with symptomatic Type 1 spinal muscular atrophy (SMA). The data showed an estimated 91% of infants (n=58) treated with Evrysdi were alive after three years of treatment. The Evrysdi-treated infants continued to improve or maintain motor functions, including the ability to swallow, sit without support, stand with support and walk while holding on, between two and three years of treatment. Without treatment, children with Type 1 SMA are never able to sit without support. The study also showed overall continued reductions in serious adverse events (SAEs) and hospitalisations over time.

Related News

GSK and Vir Biotechnology announce United States government agreement to purchase additional supply of sotrovimab, authorised for the early treatment of COVID-19

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the US Government will purchase an additional 600,0...


PRESS RELEASE Corporate Announcements

ADUHELM™ (Aducanumab) ยารักษาโรคอัลไซเมอร์ตัวแรกและตัวเดียว ที่ได้รับการอนุมัติเร่งด่วนจาก FDA

8 มิถุนายน 2021 – Biogen (Nasdaq: BIIB, CEO: Michel Vounatsos, ต่อจากนี้จะเรียกแทนว่า Biogen) และ Eisai Co., Ltd. (CEO: Haruo Naito, ต่อจากนี้จะเรียกแ...



AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU

AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionise cancer care at the 2022 Amer...


PRESS RELEASE Corporate Announcements

Terumo Aortic Announces PMDA Approval for RelayPro Endovascular Device in Japan

Terumo Aortic today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has granted approval of the RelayPro Thoracic Stent-...


PRESS RELEASE Product Launch

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509,1710

15th,17th floor South Sathorn road Yannawa

Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email :

Website :


Contact Us